Archives for posts with tag: bioelectronics

One deep pocket partnership” That has been my question for years. Why hasn’t Andy been able to make this happen? BIEL’s potential has been touted for years yet Andy default business model is to print more shares. This in-house approach to running BIEL has made the Whalens money and some flippers but not long term shareholders. The window of opportunity for BIEL to make a major move is not going to remain open much longer. We need a credible spokesperson to put a face to the product and a national ad campaign. IMHO

Worth repeating,

Advertisements

Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.
Margaret Mead

Let me start with the beginning-Bioelectronic Shareholders need to proactively start spamming every article and tweet in the Internet Universe with news of The Actipatch, otherwise the window will close on the opportunity to get this effective and non-pharmaceutical pain relief product into the hands of people so they don’t have to use dangerous and addictive narcotics for pain relief.

Earlier I tried to post a rather lengthy rant, and somewhere between “publish and preview”, I lost the entire thing except the title. So I will try to recapture the essence of it, on a computer better suited for this than my phone, from which I tried earlier.

First, let me synopsize the current situation for Bioelectronics Corporation (ticker symbol: BIEL). After literally being in oblivion, the company, which produces a device which uses electrical pulses to control and alleviate pain as opposed to drugs, finally got a grossly overdue from the most corrupt organization in the world, the FDA. It was a case of the Steve Martin school of success–be so good they can’t possibly ignore you. Still, the FDA hedges, and only gave approval for 2 out of 3 510K applications. It’s a start, and the other one is pending.

Now, if you follow the news like me, you will see we “suddenly” have an opioid crisis in this country. I say “suddenly” in quotes because there is nothing sudden about it. The media and government are “suddenly” acknowledging the crisis, in article after article, presidential tweet after presidential tweet, the facebook, newspapers, magazines. This is from the same corporate government that brought us the Afghanistan War, replete with photos of soldiers from many nations guarding…poppy fields.  The Taliban had shut opium production down before 911, but thanks to the war, Candyland is open for business, and business is booming. So booming that it created a problem for Mexican drug cartels. You see, they had been supplying Europe with H, Horse, Smack, Big Brother, but now those pesky Afghans were back in business. American tax dollars at work. So where to sell Mexican cartel heroin? Idea!!! The USA!!!!

So they saddled up  a string of mules, etc.

Now, years later, Smack is Back, and people are dropping like flies. They got hooked on legal prescriptions and then “graduate” to street drugs when their prescription gets cut off. It’s the nature of addiction.

It even impacted the presidential election. Luzerne County in Pennsylvania is an extremely Democrat Machine environment, but it was dubbed the “unhappiest place in the USA” by the USA TODAY,  dubious distinction from an even more dubious newspaper. The reasons? The economy and the high rate of teenage opioid overdoses. Luzerne County voted for Trump. Easy to imagine this cost Hillary Pennsylvania. Dying didn’t get their attention, but not voting Democrat sure did.

Now, the reader needs to trust me. I am going somewhere relevant to the title of this blog, but now we need to take a brief dive into the Hegelian Dialectic, and how it will be used to subvert America’s recovery from the opioid crisis. Also, as a disclaimer, if you think pharmaceutical companies, Mexican Drug Cartels, or corrupt politicians care about you or your families at all, and have any real desire to improve your life at their expense, I may not be able to help you.

Here is the Hegelian Dialectic, which is used by our controllers as effectively as Shaq ever used the slam dunk technique:

A problem is created, or in the case of the Opioid addiction crisis, acknowledged and publicized. A solution is presented. It’s called synthesis and antithesis.

So, now that the mainstream is admitting the opioid crisis, what will be the solution we will be presented with? What solution will Big Pharma and their paid representatives in the Media and Government present us with? This is quiz time.What do you think? Let me know when you are ready. Done? Please put down your Number Two pencil. And the Answer is:

MORE DRUGS.

Yes, the solution to the drug crisis will be drugs to treat addiction. Margaret Hamburg, the disgraced former head of the FDA and her hedge fund husband manager at the Renaissance Fund are the types of people who run the FDA, and their solution to treat pain will be more drugs, drugs with dangerous side effects which will poison people. It an alley-oop. The Media and Government beat the Drug Addiction Crisis, and present the problem. Now we need a solution! Who will save us? The same “thinkers” who got us into this mess and made money doing it will now “fix” it, and make money doing that, except they won’t fix it, BUT THEY DON’T CARE!!! Kobe Bryant alley oops it to Shaq, and slams it into the faces of the American Citizenry, and a bunch of kids in Wilkes Barre are dead of drug overdoses at age fifteen. It’s the Hegelian Dialectic, and once you see it, you can’t stop seeing it.

So what can be done? A small group of people can make a difference. They sure as heck did in 1776. America is in a horrible crisis of opioid addiction and death. Bioelectronics, PEMF, pulsed microwave, The Actipatch is at least a partial answer. We Bioelectronic Folk own the cure. We provided the partial answer in 2009, but the crooks at the FDA smacked us down. In an absolutely humiliating turnaround, the FDA were forced to admit their gross mistake, albeit halfheartedly and grudgingly.

Now, politicians and media and whining about the opioid crisis. I wrote a series of books where this crisis featured prominently, the first in 2011, called ZOMBIE WORLD ORDER. I was writing about this six years ago. We own this issue, not the media, not the government, not the pharmaceutical companies. It is ours, we just need to claim it.

So I’m calling out to all Bioelectronics Shareholders, Actipatch users (who often become shareholders), and people who have suffered from addiction and the loss of loved ones to it. Fight back. Let’s start spamming the shit out of this. When Trump tweets about the Opioid crisis, there is an opportunity to promote the Actipatch. Every article can be used for such. It’s judo, we must use their weapons against them until we get our own. This can work.

There is a point in a chess match, an athletic competition, or a game of poker where decisive action at a critical moment leads to victory. We are at this moment. We must seize it as best we can and at every opportunity. We have an economic duty to ourselves, but more importantly, a patriotic and philanthropic duty to make America  a better place and make the world a better place. Drug addiction is demonic, a win for Entropy and The Devil, and all their minions. Let’s do this!

Image result for troops guarding poppy fields

Image result for troops guarding poppy fields

Image result for troops guarding poppy fields

 

Hello readers, best wishes on my star day, as they say in Dinotopia. Linked below are some books which should be free on February 18th. Enjoy, and as always, nothing wrong with reviewing the books on Amazon. The Zombie book gets more downloads, but my metered verse play is okay, though nobody reads it.

If you follow this blog at all, you may be interested in the Bioelectronics corporation, so I will address this timely topic. I’m not getting into charts and all that at this point–that stuff has merit, and the near term key resistance point in 0.003. 0.0018 was transcended last week, and the stock closed near its 52 week high today, at 0.0024.

Very solid week trading wise, as it appears like accumulation. I’m not even going to conjecture about this. However, on a radio interview last year, Mr. Andrew Whelan of the Bioelectronics Corporation predicted the Actipatch would be in Walgreens by January. This proved optimistic, as the Patch wasn’t approved until the very end of January, and the announcement was not till early February. However, point is Whelan has been working on getting this in stores, and this should be pretty imminent. So, on relatively light volume, the stock closed high right before a three day weekend. I expect news soon, to be blunt.

BIEL (Bioelectronics Corporation’s ticker) has developed a global marketing mechanism. BIEL is global. Now, a Glaxo or a Bayer would not need this structure, as they have spent billions developing their own. However, it has served as this giant marketing campaign to introduce the Actipatch to the world. There is a lot of value added to this buyout. I cite GLAXO specifically because they are a great and visionary company, and are already involved in the field of bioelectronics, though BIEL has bested them.

I admit, when I think of this unique, disruptive technology, I view Whelan as this OLD MAN AND THE SEA character, Santiago. He silenced all critics and caught the biggest fish in the ocean. Now he has to get the prize back to shore. However, now come the sharks and predators, too dumb to catch their own fish but will try to steal his. So say a little prayer for this tiny company who caught a whale. I think Whelan is a smart and experienced guy, and is pretty much holding a royal straight flush.

Allay, the Actipatch for menstrual pain, alone makes this a billion dollar company. I have eight sisters (big family) and can appreciate the magnitude of this idea and market. This will be a tough one to get FDA clearance for, but it will eventually happen. First, though, I am still expecting the Actipatch for Back Pain to get clearance soon. There were three 510Ks, and two got clearance. My question is will the Back Patch need to be refiled citing the two cleared as precedents?

Anyway, just checking in. Trump kicked some Commie ass at his recent press conference. True or not, I will always think Trump accelerated the approval process for BIEL just by scaring all the corrupt at the FDA. Hillary and her bag girl Margaret Hamburg were running it like it was an ATM for themselves. When I say BIEL is disruptive, it means this is like a water powered car engine would be for the oil business. BIEL’s technology may someday mean the end of the drug business, at least for pain management. If I get this, after reading primary research papers on this topic and doing some of my own data analysis, you better believe people a lot smarter and better financed than me realize BIEL’s potential.  They are not as honest as me though, and I believe they tried to bury this stock.

The thing about President Trump is that nobody can probably beat The New World Order, but you have to love the people who try.

I’m expecting great things in the near term for BIEL. In six months, the chart is going to look like a straight line up, though on the day to day it appears to rising slowly and gradually building momentum. I am going to theorize that BIEL is the kind of stock that had a lot of naked shorting going on. There may be a blowout top where they have to cover, and this might be an opportunity to try to flip some of the stock and buy back in (free shares). However, we are not currently there. It’s going up, but the stock is still so undervalued I don’t expect it to ever see these levels again once it shoots past them. We’ll see.

 

The Complete Zombie World Order Trilogy

Moonlight on the Post-Apocalyptic Dinner Theater

 

Well, I’m enjoying that pleasant feeling you get when you haven’t been punked.

Champagne corks popping in Maryland, I expect, as the Whelans and crew are celebrating some long overdue FDA news tonight. Special shout out to Mr. Andrew Whelan, who always took my (rare) phone calls.

The FDA has granted OTC clearance (see below). More will be revealed, but believe me this is huuuge.

You gotta love this stock if you’re a zombie fan, because this thing keeps rising from the dead.

What happens Monday or how to play it–your guess is as good as mine. With this type of announcement, you are better off being already in, much better.

Congratulations to all the stalwarts of this stock. I admit I was about to wring some necks…soon, that’s when. What a difference a day makes.

Good luck to all the longs. Monday it’s the Hunger Games arena.We waited a long time for some fireworks, and it looks like we’ll get them. I feel vindicated, as do we all. One hates to put trust in ones scientific judgment and have a washout, but it looks like the takeaway is the FDA crunched the data and said it was efficacious.

Here is a significant point–BIEL has several other products waiting in the wings. If the FDA approved these two, the others stand a much better chance.

Celebrate by buying my book.

 

 

BioElectronics ulationsCorporation Announces US FDA OTC Clearances For Drug-free ActiPatch® Musculoskeletal Pain Therapy

 FREDERICK, MD, USA, February 3, 2017 — BioElectronics Corporation (OTC Pink: BIEL), the maker of wearable pain therapy devices, announced today that it has received over-the-counter use clearance from the US FDA for ActiPatch for the adjunctive treatment of musculoskeletal pain related to (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.

BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

Our current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The flagship product of BioElectronics Corporation is the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy for $30.00 retail. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. ActiPatch Provides:

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.

Contact:
Grace Holdings
732-335-1152

I pasted some new development about Bioelectronics below. The post is from the company by way of srinsocal from the I-hub message board. I italicized and bracketed their comment with parenthesizes.

The marathon continues.

One positive takeaway is the FDA has agreed to review data already submitted for the 510K for musculoskeletal pain, especially back pain. This possibly indicates some forth coming closure on the back pain application since it would indicate the submission is complete.

This stock needs a win, and it would be very good to get FDA approval for at least one application, as all else would logically follow even if more data is required for the other ones, specifically knee and plantar fascitis.

BIEL’s management was smart to engage lawyers to help navigate this thing. Maybe that will make a difference this time. There are only so many ways you can crunch numbers, and the FDA must be great at this, so for back pain at least, we may expect closure in a reasonable time, or at least I can’t see why we wouldn’t. I bought more.

 

POST

“Pending U.S. FDA Market Clearance for Over-the-Counter Sales

We had a second status meeting with the FDA on Wednesday, July 20, 2016. Senior Management from the Neurology and Physical Medicine Group, 4 examiners, the Head of the Physical Medicine, and the project statistician were present. The meeting went well and the tenor was very good.

Senior Management once again attended meeting showing that this is still an important priority project for the FDA

They have accepted our knee and plantar fasciitis studies as indicative of musculoskeletal pain relief and our explanation of our unique mechanism of action.

(Bingo!, Knee and Plantar Fasciitis are FDA acceptable and Mechanism of Action is no longer an issue.)

However, they would like a third study to substantiate our broader indication of use. To accommodate our request for market clearance for the relief of musculoskeletal pain, the examiners have agreed to exclusively review the back pain data from our UK Registry studies. Some of this data is peer reviewed and published. We have approximately 4,500 subject’s responses, who used the trial device for musculoskeletal back pain, as well as data on over 100 subjects demonstrating the durability of therapy over a 6 month study period for back pain.”

 

Graph Builder 6-16=